Literature DB >> 25770087

Explaining Extremity in Evaluation of Group Members: Meta-Analytic Tests of Three Theories.

B Ann Bettencourt1, Mark Manning2, Lisa Molix3, Rebecca Schlegel4, Scott Eidelman5, Monica Biernat6.   

Abstract

A meta-analysis that included more than 1,100 effect sizes tested the predictions of three theoretical perspectives that explain evaluative extremity in social judgment: complexity-extremity theory, subjective group dynamics model, and expectancy-violation theory. The work seeks to understand the ways in which group-based information interacts with person-based information to influence extremity in evaluations. Together, these three theories point to the valence of person-based information, group membership of the evaluated targets relative to the evaluator, status of the evaluators' ingroup, norm consistency of the person-based information, and incongruency of person-based information with stereotype-based expectations as moderators. Considerable support, but some limiting conditions, were found for each theoretical perspective. Implications of the results are discussed.
© 2015 by the Society for Personality and Social Psychology, Inc.

Entities:  

Keywords:  Complexity extremity; evaluative extremity; expectancy violation; impression formation; stereotyping; subjective group dynamics

Mesh:

Year:  2015        PMID: 25770087     DOI: 10.1177/1088868315574461

Source DB:  PubMed          Journal:  Pers Soc Psychol Rev        ISSN: 1532-7957


  2 in total

1.  Editor's Choice: Deliberative and non-deliberative effects of descriptive and injunctive norms on cancer screening behaviors among African Americans.

Authors:  Mark Manning; Todd Lucas; Stacy N Davis; Heiddis B Valdimarsdottir; Hayley Thompson
Journal:  Psychol Health       Date:  2019-11-20

2.  Results of an African American-targeted norm-based colorectal cancer screening intervention: a pilot study.

Authors:  Mark Manning; Todd Lucas; Hayley Thompson; Louis Penner
Journal:  J Behav Med       Date:  2022-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.